Emergency coronary artery revascularization: a possible therapy for acute myocardial infarction

The History of Primary Angioplasty and Stenting for Acute Myocardial Infarction

The evolution of the management of acute myocardial infarction (MI) has been one of the crowning achievements of modern medicine. At the turn of the twentieth century, MI was an often-fatal condition. Prolonged bed rest served as the principal treatment modality. Over the past century, insights into the pathophysiology of MI revolutionized approaches to management, with the sequential use of surgical coronary artery revascularization, thrombolytic therapy, and percutaneous coronary intervention (PCI) with primary coronary angioplasty, and placement of intracoronary stents. The benefits of prompt revascularization inspired systems of care to provide rapid access to PCI. This review provides a historical context for our current approach to primary PCI for acute MI.

Analytic Review: Thrombolytic Therapy in Acute Myocardial Infarction

The salvage of myocardium in the setting of acute myocardial infarction has long been a goal of physicians involved in the care of patients with coronary artery disease. Understanding the role of thrombosis in the pathogenesis of acute myocardial infarction has led the way to an entirely new approach to the treatment of this entity. Thrombolytic therapy has now become a widely used form of treatment with encouraging results. Both intravenous and intracoronary administration of thrombolytic agents have been shown to promote recanalization of acutely occluded coronary arteries. Results of studies using the clot-specific agent, tissue plasminogen activator, intravenously have been most encouraging; successful reperfusion has been obtained in approximately 70% of patients treated. In addition, a recent large-scale trial has shown a reduction in morbidity and mortality with the early use of thrombolytic agents.

Ongoing trials should help delineate the precise role and timing of these agents as the initial form of therapy for acute myocardial infarction. Other issues that remain unresolved are the frequency of restenosis and the role of percutaneous transluminal coronary angioplasty in addition to thrombolytic therapy in the treatment of acute myocardial infarction.

Reperfusion therapy for acute myocardial infarction: Concepts and controversies from inception to acceptance

More than 20 years of misconceptions derailed acceptance of reperfusion therapy for acute myocardial infarction (AMI). Cardiologists abandoned reperfusion for AMI using fibrinolytic therapy, explored in 1958, because they no longer attributed myocardial infarction to coronary thrombosis. Emergent aortocoronary bypass surgery, pioneered in 1968, remained controversial because of the misconception that hemorrhage into reperfused myocardium would result in infarct extension. Attempts to limit infarct size by pharmacotherapy without reperfusion dominated research in the 1970s. Myocardial necrosis was assumed to progress slowly, in a lateral direction. At least 18 hours was believed to be available for myocardial salvage. Afterload reduction and improvement of the microcirculation, but not reperfusion, were thought to provide the benefit of streptokinase therapy. Finally, coronary vasospasm was hypothesized to be the central mechanism in the pathogenesis of AMI. These misconceptions unraveled in the late 1970s. Myocardial necrosis was shown to progress in a transmural direction, as a "wave front," beginning with the subendocardium. Reperfusion within 6 hours salvaged a subepicardial ischemic zone in experimental animals. Acute angiography provided in vivo evidence of the high incidence of total coronary occlusion in the first hours of AMI. In 1978, early reperfusion by transluminal recanalization was shown to be feasible. The pathogenetic role of coronary thrombosis was definitively established in 1979 by demonstrating that intracoronary streptokinase rapidly restored flow in occluded infarct-related arteries, in contrast to intracoronary nitroglycerine which rarely did. The modern reperfusion era had dawned.

Myocardial revascularisation after acute myocardial infarction

One hundred and twenty-three patients had coronary artery bypass grafting (CABG) within 30 days of acute myocardial infarction (AMI) from May 1992 to November 1997. Commonest infarct was anterior transmural (61.8%) and commonest indication of surgery was post-infarct persistent or recurrent angina (69.1%). Ten patients were operated within 48 h and 36 between 48 h to 2 weeks of having MI. Out of these, nine patients were having infarct extension and cardiogenic shock at the time of surgery. Pre-operatively fourteen patients were on inotropes of which six also had intra-aortic balloon pump (IABP) support. All patients had complete revascularisation with 3.8+/-1.2 distal anastomoses per patient. By multivariate analysis, we found that independent predictors of post-operative morbidity [inotropes >48 h, use of IABP, ventilation >24 h, ICU stay >5 days] and complications [re-exploration, arrhythmias, pulmonary complications, wound infection, cerebrovascular accident (CVA)] were left ventricular ejection fraction (LVEF) <30%, Q-wave MI, surgery <48 h after AMI, presence of pre-operative cardiogenic shock and age >60 years (P < or = 0.01). Mortality at 30 days was 3.3%. LVEF <30%, Q-wave MI, surgery <48 h after AMI, presence of pre-operative cardiogenic shock and age >60 years were found to be independent predictors of 30 days mortality (P < or = 0.01). Ninety patients were followed up for a mean duration of 33 months (1 to 65 months). There were three late deaths and five patients developed recurrence of angina. To conclude, CABG can be carried out with low risk following AMI in stable patients for post-infarct angina. Patients who undergo urgent or emergent surgery and who have pre-operative cardiogenic shock, IABP, poor left ventricular functions, age >60 years and Q-wave MI are at increased risk.

An evaluation of streptokinase therapy in early coronary reperfusion in a primate model

Efficacy of streptokinase (SK) administered beyond the period of coronary occlusion with regard to ultimate infarct size and the extent of hemorrhagic infarction was assessed in primates. Eleven macaques underwent coronary occlusion for two hours and were then reperfused. Five of them were given a 2,000 U IV bolus of SK followed by a 10,000 U IV infusion over ninety minutes. The remaining 6 served as controls. Macaques were sacrificed seven days postocclusion. The left ventricle was sectioned parallel to the minor axis, and these were examined histologically for infarct size and hemorrhage. Multiplying the planimetric values by the thickness of the sections yielded the total volumes of left ventricle, infarction, and hemorrhage. The mean percentage of left ventricle involved in infarction in the treated group was not significantly different from the controls (14.06 +/- 6.35 versus 16.50 +/- 4.67, P > 0.10). SK-treated animals had a significantly greater volume of infarct involved with hemorrhage as compared with controls (27.1 +/- 10.8 versus 4.0 +/- 1.4, P < 0.05). SK infusions done concurrently with reperfusion following a two-hour occlusion did not result in a significant reduction or increase in the size of infarct. However, SK infusions resulted in a significant increase in the amount of hemorrhagic infarction.

Myocardial protection by a left ventricular assist device during reperfusion following acute coronary occlusion

To evaluate the effects of a left ventricular assist device (LVAD) during the reperfusion period following acute coronary occlusion, sixteen mongrel dog hearts were subjected to 1 hour's occlusion of the circumflex coronary artery and then reperfused for 6 hours. In seven control dogs (control group), the hearts were reperfused without any support. In nine LVAD dogs (LVAD group), however, the left ventricles were supported by the application of a pneumatic driven diaphragm-type pump for 5 hours and then reperfused for another hour without any device. Triphenyltetrazolium chloride was used to determine the extent of infarction. The results showed a significant reduction in the area of infarct (AI) as a percentage of the area at risk (AR) in the LVAD group compared with the control group, the AI/AR being 22.3 per cent for the control group versus 4.8 per cent for the LVAD group (p less than 0.05). The cardiac output was also significantly higher in the LVAD group compared with the control group. The per cent systolic shortening in the ischemic region of the LVAD group showed a significantly better recovery, being 75.8 per cent for the LVAD group versus 24.4 per cent for the control group (p less than 0.01). It was concluded that the application of a LVAD during reperfusion after 1 hour's coronary occlusion results in a significant reduction of infarct size and provides improvement in both regional and global cardiac function.

Medical and surgical management of early Q wave myocardial infarction. I. Effects of surgical reperfusion on survival, recurrent myocardial infarction, sudden death and functional class at 10 or more years of follow-up

To define the outcome of patients given medical or surgical therapy for Q wave myocardial infarction, 387 patients were followed up for 10 to 13 years (mean 11.4). On study entry the groups had similar distributions for variables such as mean age, gender, previous myocardial infarction, abnormal creatine kinase activity, area of infarction, number of vessels diseased and clinical classification. The hospital mortality rate of the medical versus surgical group was 11.5% (23 of 200) versus 5.8% (11 of 187) (p = 0.07). Early reperfusion (that is, less than or equal to 6 h) resulted in a lower mortality rate than did medical therapy--2% (2 of 100) versus 11.5% (23 of 200) (p less than 0.05)--whereas the hospital mortality rate with late reperfusion was 10.3% (9 of 87). The long-term mortality rate of the medical and surgical groups was 41% (82 of 200) versus 27% (51 of 187) (p = 0.0007) with use of an adjusted Cox proportional hazards model. In the survivors, the differences between medical and surgical groups in recurrent myocardial infarction, mortality associated with reinfarction and sudden death were prospectively followed and evaluated by the life table method. Recurrent myocardial infarction was not prevented by surgical reperfusion or medical therapy (23% in both groups), however, the mortality rate in patients with recurrent infarction was higher in the medical therapy group--36.6% (15 of 41) versus 17.5% (7 of 40) (p = 0.04). The mortality difference did not depend on early or late surgical reperfusion. In the in-hospital survivors, the incidence of sudden death was 17.5% in the medical (31 of 177) versus 7.4% (13 of 176) in the surgical group (p = 0.01). This difference was much more pronounced in the early reperfusion group. Functional class was significantly lower than that for medical therapy in the early reperfusion but not the late reperfusion group. Thus, in comparable groups given medical and surgical therapy for acute myocardial infarction and followed up for greater than or equal to 10 years, surgical reperfusion appears to offer improved longevity in selected cases (when implemented early) but does not prevent recurrent myocardial infarction. The associated mortality with recurrent myocardial infarction is less as is the incidence of sudden death. Finally, lower functional class occurs most often in patients given early reperfusion.

Increased protein C and fibrinopeptide A concentration in patients with angina

Protein C and fibrinopeptide A (FpA) levels in plasma were measured in 30 controls and in two groups of patients with angina. The first group was formed by 27 patients suffering from spontaneous ischemic attacks (active angina). The second one was formed by patients who had previously suffered from angina, but were free from myocardial ischemic attacks for at least one month (inactive angina). Protein C (measured by electroimmunoassay) and FpA (radioimmunoassay) were higher than controls in both groups but were significantly higher in patients with active angina than in patients with inactive angina. A clear trend toward a linear correlation existed between protein C and FpA levels, though it did not reach the statistical significance. These results confirm a significant involvement of blood clotting system in ischemic heart disease and specially in active angina.

Impact of different reperfusion modalities on ventricular function after acute myocardial infarction

Single-plane contrast ventriculography was performed on admission and before hospital discharge in more than 200 patients with acute myocardial infarction participating in a series of prospective clinical trials including intracoronary streptokinase, percutaneous transluminal coronary angioplasty (PTCA), intravenous tissue plasminogen activator (rt-PA) and thrombolysis (intravenous rt-PA or streptokinase) followed by PTCA. Both global ejection fraction (EF) and regional wall motion of the infarct zone were measured to assess serial changes. Patients treated with intracoronary streptokinase 3.6 +/- 1.8 hours after symptom onset had no increase in EF (mean change 1 +/- 6%, difference not significant [NS]), but patients treated with primary PTCA at 3.0 +/- 1.2 hours did (mean improvement 8 +/- 7%, p less than 0.001). Patients treated with sequential intravenous streptokinase and PTCA 2.6 +/- 1.3 hours after symptom onset showed similar improvement in EF (mean change 6 +/- 12%, p less than 0.002). Patients treated with rt-PA had no change in EF whether treated with rt-PA alone or rt-PA followed by immediate angioplasty (mean change -2 +/- 8% and 0.5 +/- 8%, p = NS, respectively). When angioplasty was used in patients with persistent occlusion after thrombolytic therapy, EF improved in those who had received intravenous streptokinase (mean change 10 +/- 7%, p less than 0.002), but not those who had received rt-PA (+0.5%, p = NS). However, infarct zone regional wall motion improved in patients treated with intracoronary streptokinase (+0.59 +/- 0.79 standard deviation/chord, p less than 0.05), primary PTCA (+1.32 +/- 1.32, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Coronary angioplasty immediately after thrombolysis in 115 consecutive patients with acute myocardial infarction

Between September 1981 and May 1986, coronary angioplasty immediately after intracoronary thrombolysis was attempted in 115 patients with acute myocardial infarction. The present study describes our experience with this combined procedure. Primary success was achieved in 102 patients (89%). Before discharge, 79 of these patients agreed to be restudied angiographically. The infarct-related vessel was still patent in 71 patients (patency rate of 90%). Sequential left ventricular angiograms of quality sufficient to allow automated analysis were obtained in 58 patients. Global ejection fraction improved significantly from 52 +/- 10% to 55 +/- 9% (p = 0.01) from the acute to the chronic stage. In patients with anterior infarction, the increase in global ejection fraction was primarily the result of significant improvement of the regional myocardial function of the infarct zone. No significant changes in global and regional myocardial function could be seen in patients with inferior infarction. However, when patients in whom the infarct-related vessel was reoccluded at follow-up angiography are excluded from analysis, the global and regional myocardial function did improve significantly irrespective of the location of the infarct. Median clinical follow-up of 20 months (range 4 to 50) resulted in an overall mortality rate of 4%. Preservation of global and regional left ventricular function with a low mortality rate suggests that immediate coronary angioplasty after thrombolysis can be safely used to provide reperfusion in the setting of acute myocardial infarction and that this combined procedure may be the optimal mode of therapy. Further randomized studies are warranted to precisely define the role of coronary angioplasty in acute myocardial infarction.

Anesthetic implications for the management of patients with acute myocardial infarction: a matched cohort study of patients undergoing emergency myocardial revascularization

Emergency coronary artery bypass grafting (CABG) is advocated as a treatment of acute myocardial infarction (AMI). To attempt to define anesthetic management problems in this patient group, a retrospective study was conducted comparing the perioperative courses of 23 patients undergoing emergency CABG during AMI with 23 elective patients, individually matched for gender, operating surgeon, ejection fraction, and aortic crossclamp time. The 23 AMI patients were anesthetized 5.98 +/- 3.0 (range 1.5 to 11.0) hours after the onset of chest pain. Anesthetic agents were similar for both groups. Induction of anesthesia was well tolerated by AMI patients. Tolerance of cardioplegic arrest was impaired in the AMI group as evidenced by the sharp increase in frequency of inotropic support required to discontinue bypass in the AMI group compared to elective patients (12/23 v 3/23; P less than .005). Fifteen AMI patients who received preoperative streptokinase had greater postoperative bleeding. Three AMI patients died postoperatively. The number of patients requiring prolonged postoperative ventilation and extended ICU care was higher in the AMI group. It is concluded that patients undergoing emergency CABG during AMI represent a greater risk than elective patients. They have a higher incidence of myocardial dysfunction following cardioplegic arrest during bypass. Those who receive preoperative thrombolytic therapy exhibit greater bleeding tendencies.

Surgical treatment of acute myocardial infarction

Thus, in 1987, the following indications for surgical treatment of acute myocardial infarction are: 1) acute evolving myocardial infarction less than six hours from onset, in patients in whom PTCA or streptokinase, depending on the coronary anatomy, has been unsuccessful; in single vessel disease, CABG is unlikely; in multiple-vessel disease, CABG is preferable to SK/PTCA therapy unless a very major "culprit" lesion can be identified with certainty; 2) post-infarction angina hours to days after a transmural myocardial infarction unyielding to maximal medical therapy and in patients with a coronary artery obstruction not amenable to PTCA; 3) occlusion of a coronary artery during cardiac catheterization that cannot be fixed by PTCA and/or streptokinase; 4) occlusion of a coronary artery during PTCA causing hemodynamic obstruction and threatened myocardium subtended by the obstructed coronary artery; 5) balloon-dependent patients in cardiogenic shock without mechanical defects who have adequate residual left ventricular function as determined by regional wall motion studies; 6) ventricular septal defect secondary to myocardial infarction unless there is terminal organ damage; 7) mitral valve replacement with or without coronary bypass for acute papillary muscle rupture; 8) semi-emergent cardiac transplantation, either with or without a mechanical bridge to transplant in young individuals (less than 50 years) who have suffered massive destruction of left ventricular myocardium by an acute coronary occlusion with or without recurring ventricular tachyarrhythmias. Ejection fraction in this clinical category is always under 0.20 and usually under 0.15.

Differential effects of reperfusion on incidence of ventricular arrhythmias and recovery of ventricular function at 4 days following coronary occlusion

To determine the influence of coronary reperfusion on ventricular arrhythmias and ventricular function at 4 days post occlusion, anesthetized dogs randomly received no occlusion (sham), permanent occlusion, or 1-, 2-, 3-, 4-, or 6-hour occlusions of the left anterior descending coronary artery, followed by reperfusion. An ambulatory ECG was recorded between 78 and 96 hours. The total runs of ventricular tachycardia were 1 +/- 0 (sham), 155 +/- 101 (1 hour), 66 +/- 32 (2 hours), 56 +/- 35 (3 hours), 167 +/- 68 (4 hours), 942 +/- 618 (6 hours), and 1422 +/- 486 (permanent occlusion); the runs of ventricular tachycardia were significantly less in the combined 1- to 4-hour groups (93 +/- 24) compared to the 6-hour and permanent occlusion groups (1282 +/- 384; p less than 0.006). Similar results were obtained for the number of hours in which ventricular tachycardia or frequent ventricular premature beats occurred. At 96 hours, improvement in percent systolic wall thickening of the ischemic myocardium assessed by two-dimensional echocardiography was seen in the group reperfused at 1 hour (p less than 0.01). Similar results were obtained for the reduction in degrees of wall circumference showing systolic thinning. In summary, at 4 days post occlusion in a dog model, spontaneous ventricular arrhythmias are reduced by reperfusion within 4 hours, while return of ventricular function is only improved by reperfusion within approximately 1 hour of coronary occlusion.

Early and late results following emergency isolated myocardial revascularization during hypothermic fibrillatory arrest

From January, 1982, through November, 1985, 127 consecutive patients had emergency isolated myocardial revascularization during hypothermic fibrillatory arrest. Mean age was 62.3 years; 27 patients (21.2%) were older than 70 years. Mean ejection fraction was 0.49, with 20 (15.7%) less than 0.35. Intraaortic balloons were present in 109 patients (85.8%). Nitroglycerin was given intravenously to 97 patients (76.3%), and thrombolytic therapy had been used in 12 patients (9.4%). Indications for operation were postinfarction ischemia in 61 patients (48.0%), preinfarction unstable angina in 44 (34.6%), acute ischemia following failed percutaneous angioplasty in 14 (11.0%), and cardiogenic shock in 8 (6.3%). Operation was performed within 1 week of an acute infarction in 47 patients. Mean number of grafts per patient was 4.1. There was 1 hospital death (0.8%) and 1 perioperative myocardial infarction (0.8%). Actuarial survival at 45 months was 90.8 +/- 2.9%. Mean New York Heart Association Classification for the 117 long-term survivors was 1.12.

Infarct size--can it be measured or modified in humans?

Despite more than 15 years of intensive experimental and clinical research in the general area of limiting infarct size, no treatment has been shown to be so efficacious and relatively free of side effects that its routine use can be recommended. In addition, there is no ideal means of measuring infarct size as yet. However, considerable progress has been made in understanding mechanisms responsible for irreversible cellular injury and in identifying factors and anatomic alterations responsible for or contributing to the development of transmural (Q wave) and non-transmural (non-Q wave) myocardial infarcts. Interventions are available that are capable of causing rapid coronary thrombolysis, and techniques are becoming available tht have increasing power to size myocardial infarcts and estimate both segmental and ventricular function. Experimental studies have also suggested a potential benefit from a combination of reperfusion therapy with selected pharmacologic intervention in reducing infarct size and preserving ventricular function. It seems likely that this general area will remain an intensive area of clinical research in the immediate future.

Retrograde coronary sinus perfusion prevents infarct extension during intraoperative global ischemic arrest

To determine whether continuous infusion of cardioplegia retrograde through the coronary sinus could improve the salvage of infarcting myocardium, 54 pigs were utilized in a region at risk model. All hearts underwent 30 minutes of reversible coronary artery occlusion, and were divided into six groups. Group 1 served as controls and underwent two hours of coronary reflow without global ischemic arrest. The remaining five groups were subjected to 45 minutes of cardioplegia-induced hypothermic arrest followed by two hours of normothermic reflow. Group 2 had a single infusion of crystalloid cardioplegia, and Group 3 received an oxygenated perfluorocarbon cardioplegic solution initially and again after 20 minutes of ischemia. After initial cardiac arrest with crystalloid cardioplegia, all hearts in Groups 4, 5, and 6 underwent a continuous infusion of a cardioplegic solution retrograde through the coronary sinus. Group 4 received a nonoxygenated crystalloid cardioplegic solution, Group 5 received an oxygenated crystalloid cardioplegic solution, and Group 6 received an oxygenated perfluorocarbon cardioplegic solution. With results expressed as the percent of infarcted myocardium within the region at risk, Group 2 hearts, which received only antegrade cardioplegia, had a mean infarct size of 44.8 +/- 6.3%, a 2.2-fold increase over controls (p less than 0.05). While antegrade delivery of oxygenated perfluorocarbon cardioplegia (Group 3) and coronary sinus perfusion with nonoxygenated crystalloid cardioplegia (Group 4) limited infarct size to 33.6 +/- 4.7% and 35.3 +/- 5.4%, respectively, only oxygenated cardioplegia delivered retrograde through the coronary sinus (Groups 5 and 6) completely prevented infarct extension during global ischemic arrest.(ABSTRACT TRUNCATED AT 250 WORDS)

A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction

We randomly assigned 56 patients who presented within 12 hours of their first symptoms of acute myocardial infarction to treatment with either intracoronary streptokinase or coronary angioplasty. The mean (+/- SD) duration of symptoms (3.0 +/- 1.2 hours in the group treated with angioplasty vs. 3.6 +/- 1.8 in the group treated with streptokinase; P not significant) and time to recanalization (4.1 +/- 1.4 hours vs. 4.8 +/- 1.7 hours; P not significant) were similar in both groups. Coronary recanalization was achieved in 83 percent of the patients treated with angioplasty and in 85 percent of those treated with streptokinase (P not significant). Residual luminal stenosis in the coronary artery was significantly decreased after angioplasty, as compared with streptokinase therapy (43 +/- 31 percent of patients vs. 83 +/- 17; P less than 0.001). Residual stenosis of 70 percent or more was present in 4 percent of the angioplasty-treated patients and in 83 percent of the streptokinase-treated patients (P less than 0.01). Ventricular function after therapy was assessed by serial contrast ventriculograms. Increases in both global ejection fraction (8 +/- 7 percent vs. 1 +/- 6; P less than 0.001) and regional wall motion (+1.32 +/- 1.32 SD vs. +0.59 +/- 0.79 SD; P less than 0.05) were greater for the angioplasty group. We conclude that angioplasty and streptokinase produce similar rates of early coronary reperfusion during evolving transmural myocardial infarction. However, angioplasty is significantly more effective in alleviating the underlying coronary stenoses, and this may result in more effective preservation of ventricular function after therapy.

Effects of staged versus sudden reperfusion after acute coronary occlusion in the dog

Sudden and staged reperfusion after experimental coronary artery occlusion was studied in relation to recovery of cardiac function and postreperfusion arrhythmias. Eighteen closed chest dogs with 3 hour intracoronary balloon occlusion of the proximal left anterior descending coronary artery were studied using two-dimensional echocardiography over a period of 3 weeks after reperfusion. Nine dogs had sudden reperfusion by abrupt balloon deflation. In nine other dogs reperfusion was staged with partial reflow (20 ml/min) for 2 hours through the central lumen of the catheter during persisting intracoronary balloon inflation, followed by balloon deflation and full reperfusion. Within the first 30 minutes of sudden reperfusion, ischemic zone end-diastolic wall thickness increased significantly, from 6.8 +/- 0.3 mm at 3 hours of occlusion to 10.2 +/- 2.6 mm (p less than 0.05). In contrast, at 30 minutes of partial reflow, wall thickness was 7.5 +/- 0.7 versus 6.8 +/- 0.7 mm at 3 hours of occlusion (NS). A small temporary increase in end-diastolic wall thickness was noted when full reflow was established after 2 hours of staged reperfusion. However, wall thickness was normal on the first day in the staged reperfusion series, while sudden reperfusion delayed recovery to 7 days. Function of the ischemic zone failed to improve substantially until day 3 after sudden reperfusion, whereas it improved consistently starting as early as 30 minutes after institution of the staged reperfusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Coronary bypass surgery early after thrombolytic therapy for acute myocardial infarction

The safety of coronary bypass operations after coronary reperfusion with streptokinase for acute myocardial infarction is not well documented. Therefore we studied 23 consecutive patients (mean age, 59.5 years; 22 men) undergoing bypass operations a median of 5 days (range, 1 to 23 days) after thrombolysis (streptokinase). The control group consisted of 169 concurrent patients of similar mean age (58.8 years) having bypass operations for standard indications. The preoperative angiographic ejection fraction was 68 +/- 14% in the control patients and 61 +/- 14% in the streptokinase group (p less than 0.05). The number of diseased vessels (70% stenosis or greater) averaged 2.6 in control and 2.3 in streptokinase patients. A previous myocardial infarction had occurred in 42% of the controls and all of the streptokinase patients. Aortic cross-clamp times did not differ between the two groups (80 +/- 35 minutes for the controls and 68 +/- 25 minutes for the streptokinase group). Cardiopulmonary bypass times were similar: 108 +/- 45 minutes in the controls versus 109 +/- 28 minutes in the streptokinase group. Grafts per patient averaged 3.7 +/- 1.5 for the controls versus 2.8 +/- 1.1 for the streptokinase patients (p less than 0.01). Difficult operative hemostasis was noted in 4% of both groups. Inotropic support was given postoperatively to 11% of the control and 13% of the streptokinase patients (p = not significant). Measured blood loss during the first 48 hours postoperatively was similar, averaging 809 ml in controls and 776 ml in the streptokinase group. Blood product replacement was also comparable: mean, 713 ml in the control group versus 759 ml in the streptokinase group.(ABSTRACT TRUNCATED AT 250 WORDS)

Reperfusion protocol and results in 738 patients with evolving myocardial infarction

Reperfusion is an accepted therapy for evolving myocardial infarction (MI), as successful reperfusion reduces morbidity and mortality. A team approach between the cardiologists and cardiac surgeons must be applied to achieve reperfusion within a finite time from the onset of coronary thrombosis. Analysis of 738 patients grouped them by successful reperfusion in the catheterization laboratory versus the operating room. Factors that predict wall motion recovery related to the onset of clinical symptoms, time to reperfusion, coronary anatomy, and collateral network were reviewed. Comparisons were made between patients with stable versus unstable hemodynamics and successful or unsuccessful reperfusion. Of the 738 patients, the initial attempt at reperfusion was made in the catheterization laboratory with success in 331. These patients all had primarily single-vessel disease. With multiple-vessel disease identified at catheterization, 189 patients were immediately treated by surgical reperfusion. This method also was used for an additional 72 patients in whom reperfusion could not be achieved in the catheterization laboratory. Of the entire group of 738 patients, 146 (20%) could not be reperfused. Overall mortality for the 592 patients reperfused was 4.9% compared with 17% for those who could not be reperfused. Time was critical for wall motion recovery if no collaterals were demonstrated on angiography. If collaterals were present, time to reperfusion was not critical. Wall motion recovered in 90% of the patients if the endocardial anatomy on the initial angiogram was smooth. However, if the endocardial anatomy looked mottled and irregular, less than 10% of patients had recovery of wall motion.(ABSTRACT TRUNCATED AT 250 WORDS)

[Emergency coronary surgery after transluminal coronary angioplasty]

Twenty-five patients underwent emergency coronary arterial bypass surgery immediately after attempted percutaneous transluminal coronary angioplasty (PTCA). The average time between the onset of PTCA complication and revascularization was 90 min (30-120 min). The surgical indications, the anaesthesia and the perioperative intensive care were analysed. No acute complication was observed during the anaesthesia. Peroperative findings defined two groups: the first "organic" (coronary arterial dissection and/or occlusive coronary thrombi; n = 15), the second "functional" (coronary arterial spasm; n = 10). The rate of perioperative myocardial infarction was significantly higher in the "organic" group. In this group, at the end of the cardiopulmonary bypass, a higher number of patients required circulatory assistance and/or an antiarrhythmic agent, as well inotropic drugs.

Reperfusion before global ischemic arrest improves the salvage of infarcting myocardium

To study the effect of hypothermic global ischemic arrest on an evolving myocardial infarction and of perfusion of the ischemic zone or region at risk before global ischemia, 62 farm pigs underwent 15, 30, or 60 minutes of reversible coronary occlusion. Twenty-eight of these animals served as controls: reflow to the region at risk was established by removal of the coronary occluder without the addition of global ischemia. Another 26 animals had similar periods of coronary occlusion and then were placed on cardiopulmonary bypass; they underwent aortic cross-clamping and cardioplegia-induced global hypothermic arrest for 45 minutes. Eight additional pigs had two hours of reflow to the region at risk after removal of the occluder and before global ischemic arrest. When superimposed on regional ischemia, global ischemia resulted in a 6-fold increase in infarct size after 15 minutes of coronary occlusion (p less than 0.05), a 2.2-fold increase after 30 minutes of coronary occlusion (p less than 0.05), and no significant increase after 60 minutes of coronary occlusion. Reperfusion prior to global ischemia completely prevented infarct extension with 0.4% less infarction (not significant) in this group versus the controls without global ischemia. These results clearly demonstrate that infarct extension occurring when global ischemia is superimposed on regional ischemia is greatest early in infarct evolution but that reflow to the region at risk before global ischemic arrest prevents the additional infarction.(ABSTRACT TRUNCATED AT 250 WORDS)

Synchronized coronary venous retroperfusion: prompt improvement of left ventricular function in experimental myocardial ischemia

The effect of synchronized coronary venous retroperfusion of arterial blood on cardiac function after experimental coronary occlusion was examined by two-dimensional echocardiography. In 18 closed chest anesthetized dogs, the proximal left anterior descending coronary artery was occluded for 6 hours with an intracoronary balloon catheter. Eight of these animals served as untreated controls. Ten were treated with synchronized retroperfusion initiated 30 minutes after occlusion, and treatment was interrupted for 5 minutes at 1 hour after occlusion for study of the rapidity of retroperfusion response. Quantitative echographic analysis yielded global ejection fraction and regional indexes of contraction in a low left ventricular short-axis section, including segmental systolic area change, systolic wall thickening and end-diastolic wall thickness. At 6 hours after occlusion, ejection fraction had decreased from 50.7 +/- 4.9% to 28.1 +/- 7.7% (mean +/- standard deviation) in control dogs, but was significantly (p less than 0.01) less depressed in treated dogs (from 55.9 +/- 5.2 to 41.8 +/- 9.3%). The ischemic zone fractional area change at 30 minutes of occlusion exhibited a marked depression in both groups, after which the dysfunction persisted in the control dogs, but was largely reversed with retroperfusion from 6.0 +/- 6.5 to 35.9 +/- 15.9% at 6 hours of occlusion (p less than 0.01). Brief interruption of retroperfusion 1 hour after occlusion reduced ischemic zone fractional area change from 33.0 +/- 14.9 to 12.2 +/- 9.5% (p less than 0.01). This depression was promptly reversed to 33.6 +/- 12.2% when retroperfusion was resumed. Segmental wall thickening followed a similar trend.(ABSTRACT TRUNCATED AT 250 WORDS)